# Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

> **NCT06628908** · PHASE3 · RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 1100 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** Suzetrigine
- **DRUG:** Placebo (matched to SUZ)
- **DRUG:** Pregabalin
- **DRUG:** Placebo (matched to Pregabalin)

## Key facts

- **NCT ID:** NCT06628908
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06628908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06628908, "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06628908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*